LivaNova PLC

LIVN Healthcare Medical Devices

LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.8%, EPS grew 296.0%, free cash flow fell 26.7% and total debt fell 31.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

77.60 0.90 −1.15%
Market cap
$4.3B
P/E
22.5×
Fwd P/E
26.0×
Dividend yield
—
F-score
4/9
Altman Z
1.74
Beneish M
−3.30
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — 4 4 2 6 6 5 7 4
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 157.94 39.92 0.00
Altman Z-Score
2.76 4.09 2.54 2.13 1.26 2.82 1.68 1.60 1.79 1.74
P/S ratio
2.30 3.80 4.01 3.36 3.44 4.28 2.89 2.36 2.00 2.42
Altman Z″-Score (non-manufacturers)
4.19 4.19 0.63 0.49 0.19 0.11 1.23 1.44 2.26 0.72
P/FCF ratio
48.29 65.95 46.43 0.00 0.00 60.06 73.68 72.24 18.93 18.94
P/Operating CF
54.27 217.84 212.35 1,272.49 86.99 132.22 157.79 50.52 31.91 40.73
Beneish M-Score
— (2.32) (3.12) (2.77) (3.36) (2.93) (2.95) (2.35) (2.82) (3.30)
P/B ratio
1.30 2.12 2.95 2.64 2.90 3.42 2.44 2.13 1.90 2.80
Price to Tangible BV
3.86 7.77 0.00 0.00 0.00 0.00 41.99 11.67 7.54 18.94
EV/Sales
2.38 3.86 4.12 3.62 3.87 4.31 2.91 2.37 1.93 2.23
EV/EBITDA
14.09 18.48 0.00 0.00 0.00 53.16 22.59 239.67 11.97 10.98
EV/Operating CF
25.48 42.73 37.82 (43.05) (45.58) 43.48 42.58 36.51 13.20 12.18
EV/FCF
50.10 66.85 47.70 (32.92) (30.73) 60.48 74.33 72.48 18.21 17.48
Quick Ratio
0.72 0.93 0.61 0.62 1.41 0.56 2.35 2.37 2.34 1.05
Current Ratio
2.32 2.14 1.07 1.07 2.29 0.97 2.98 2.95 2.87 1.36
Net Debt/EBITDA
0.51 0.25 (0.74) (6.29) (2.49) 0.38 0.20 0.77 (0.48) (0.92)
Debt/Assets
5.24% 5.83% 6.60% 14.00% 27.32% 10.88% 23.60% 24.15% 25.04% 14.45%
Debt/Equity
0.07 0.08 0.11 0.24 0.59 0.19 0.45 0.46 0.48 0.31
Asset Turnover
0.39 0.42 0.44 0.44 0.39 0.45 0.45 0.49 0.51 0.54
Operating CF/Net income
(1.44) (3.64) (0.64) 0.58 0.23 (0.75) (0.81) 4.27 2.89 (1.05)
Capex/Depreciation
(0.29) (0.25) (0.28) (0.22) (0.31) (0.30) (0.13) (0.42) (0.65) (0.89)
Interest Coverage
3.15 12.37 (25.25) (11.37) (6.71) (0.02) (1.59) (1.16) 2.05 4.05
ROE
(3.57%) (1.42%) (11.41%) (10.92%) (27.98%) (11.30%) (6.89%) 1.41% 4.87% (19.24%)
ROA
(2.56%) (1.04%) (7.50%) (6.35%) (14.50%) (5.90%) (3.84%) 0.74% 2.56% (9.49%)
ROIC
1.17% 3.23% (9.54%) (6.46%) (11.32%) (0.04%) (3.89%) (3.33%) 6.59% 13.24%
Return on Tangible Assets
(9.42%) (3.82%) (83.09%) (72.23%) (61.98%) (102.68%) (11.72%) 2.17% 6.98% (45.22%)
Average Days of Receivables
80.67 101.73 84.46 86.78 72.03 65.34 65.41 68.05 56.25 56.80
Research and Development Expense of Revenue
8.51% 10.82% 13.18% 13.54% 16.37% 17.71% 15.25% 16.80% 14.56% 13.38%
Selling, General and Administrative Expense of Revenue
36.81% 37.55% 42.00% 48.74% 47.80% 45.58% 45.92% 43.58% 40.60% 39.54%
Intangible Assets out of Total Assets
0.48 0.53 0.68 0.63 0.57 0.59 0.50 0.43 0.39 0.39
Share Based Compensation of Revenue
2.03% 1.88% 2.43% 3.00% 3.76% 3.92% 4.39% 3.15% 2.71% 2.61%
Graham Net Nets
0.08 0.05 (0.12) (0.13) (0.18) (0.05) (0.07) (0.06) (0.02) (0.09)
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.06 25.21 0.00
Earnings Yield
(2.85%) (0.65%) (4.27%) (4.26%) (10.69%) (3.04%) (2.92%) 0.63% 2.50% (7.23%)
Free Cash Flow Yield
2.07% 1.52% 2.15% (3.27%) (3.66%) 1.67% 1.36% 1.38% 5.28% 5.28%
Revenue per Share
19.75 21.02 22.83 22.42 19.23 20.45 19.11 21.39 23.11 25.45
Operating CF per Share
1.85 1.90 2.48 (1.89) (1.63) 2.03 1.31 1.39 3.37 4.66
Capex per Share
(0.76) (0.58) (0.49) (0.58) (0.72) (0.50) (0.50) (0.63) (0.87) (1.35)
Free Cash Flow per Share
1.08 1.31 1.99 (2.46) (2.36) 1.52 0.81 0.76 2.51 3.31
Cash per Share
0.81 1.94 0.97 1.26 5.20 4.11 9.64 10.71 13.34 11.65
Shareholders Equity per Share
34.93 37.70 31.01 28.62 22.83 25.57 22.58 23.69 24.34 22.00
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
34.93 37.70 31.01 28.62 22.83 25.57 22.58 23.69 24.34 22.00
Free Cash Flow
52.93 63.17 96.71 (119.12) (114.45) 77.07 43.40 41.09 136.02 180.57
Working Capital
462.80 463.84 36.55 36.89 398.99 (17.79) 588.74 653.18 735.06 293.54
Capital Expenditures
(37.22) (28.17) (23.78) (27.98) (35.02) (25.48) (26.52) (33.83) (47.02) (73.77)
Net Current Asset Value
176.97 181.28 (512.67) (478.64) (582.65) (227.12) (201.01) (163.78) (58.94) (304.45)
EV/EBIT
68.69 40.45 0.00 0.00 0.00 0.00 0.00 0.00 18.72 15.53
Capex to Sales
0.04 0.03 0.02 0.03 0.04 0.02 0.03 0.03 0.04 0.05
Price to Operating Income
66.20 39.90 0.00 0.00 0.00 0.00 0.00 0.00 19.46 16.83
Other line items
Depreciation/Fixed assets
0.64 0.60 0.44 0.70 0.69 0.56 1.42 0.52 0.43 0.34
Cash ROIC
2.83% 3.07% 5.63% (6.68%) (5.67%) 4.42% 1.92% 1.68% 5.09% 8.16%
Accounts Receivable Turnover
3.97 4.09 4.11 4.22 4.23 5.60 5.55 5.79 6.14 6.79
Accounts Payable Turnover
4.47 4.57 4.57 4.43 4.26 4.65 4.42 5.13 5.31 5.37
Inventory Turnover
2.35 2.60 2.50 2.27 2.43 2.98 2.67 2.87 2.71 2.87
Average Days of Payables
64.77 87.00 75.29 87.00 79.21 75.36 86.22 74.19 63.63 79.12
Days of Inventory on Hand
119.77 146.30 150.65 166.27 123.95 117.29 150.12 135.72 134.67 134.13
Average Receivables
242.80 247.70 269.14 256.95 221.06 184.86 184.23 199.09 204.12 204.57
Average Payables
90.76 78.92 81.33 81.31 79.78 70.83 71.16 77.58 75.29 83.44
Average Inventory
172.73 138.74 149.00 158.84 139.72 110.56 117.61 138.63 147.73 156.13
Average Assets
2,450.69 2,423.26 2,526.80 2,480.75 2,405.88 2,300.46 2,247.86 2,362.17 2,467.98 2,556.22
Average Common Equity
1,759.19 1,761.11 1,659.53 1,443.73 1,246.49 1,201.96 1,251.13 1,242.63 1,298.94 1,260.12

Fold the line items

Columns are period end dates